A comparative-effectiveness study that spanned the dominance of SARS-CoV-2 variants of concern finds that the antiviral drug remdesivir significantly reduced in-hospital COVID-19 death rates among adults receiving supplemental oxygen on admission.
Rates of new-onset type 2 diabetes climbed 62%—and type 1 diabetes increased 17%—among U.S. youth after the COVID-19 pandemic began, especially in Black and Hispanic children.